Drug Coverage

An Avalere review finds that the proportion of generic drugs covered on lower tiers (with generally lower out-of-pocket costs for patients) in Part D plans have decreased.

Hospitalization, disability, having private high-deductible, Medicare Advantage, or no coverage were risk factors associated with medical debt.

Approved in May 2022, Tibsovo is the first therapy targeting cancer metabolism for older patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

The additions include apps to help people better manage their sleep issues, anxiety, alcohol and opioid use disorders, and inflammatory conditions.

Jeffrey A. Shaman, Ph.D., chief science officer at Coriell Life Sciences, talked about how pharmacogenomics can inform medication management.

Kali Panagos, Pharm.D., at ARMSRx, discusses the growing trend of copay assistance programs and alternative funding solutions that can help provide access to expensive specialty therapies.

Because of a generic is now available, Toviaz has been removed and up-tiered on Prime’s Medicare formularies.

Prime Therapeutics’ predictive model was able to identify members with high breast cancer pharmacy and medical claims to help clients better manage drug spend.

PSG’s latest Artemetrx specialty spend report finds that, as with 2020, claim utilization continues to drive the trend.

Ryaltris is a fixed-dose combination therapy that provides relief for both nasal and ocular symptoms of seasonal allergic rhinitis in a nasal spray.

The direct-to-consumer pharmacy also added 13 new products, and now carries almost 1,000 medications.

Survey participants said their drug costs have gone up and almost a third had trouble paying for food and housing because of high drug costs.

Hyftor was approved in April 2022 to treat patients with the rare disease facial angiofibroma associated with tuberous sclerosis complex.

Payer coverage and the prior authorization process continue to be barriers for the adoption of biosimilars, according to a new Vizient survey.

The PBM is removing four products and adding one product back to its standard control formulary.

Out-of-pocket costs decreased for those with insurance but rose for those without insurance, finds RAND study.

The rate reflects a continued trend toward moderation of the overall increase in drug prices.

Shabbir J. Imber Safdar, executive director, Partnership for Safe Medicines, talks about efforts to address counterfeit drugs in the U.S. supply chain.

Sean Dickson of West Health Policy Center discusses Reuters' analysis of drug launch prices.

A clinical trial showed Dyanavel XR tablets were bioequivalent to the extended-release oral suspension formulation of Dyanavel.

Zoryve is a next-generation topical PDE4 inhibitor to treat adults and adolescents with plaque psoriasis.

Those who spoke at a recent webinar discussed the prescription drug elements of the Inflation Reduction Act, which recently passed in the House, and the impact it will have on Medicare and its beneficiaries.

Susan Lang, CEO and founder of XIL Health, talks about the shifting trends and pressures that have led to a misalignment between the PBMs, their clients and consumers.

Abiraterone is used together with prednisone to treat patients with metastatic prostate cancer.

The Inflation Reduction Act also allows Medicare to negotiate prices on some drugs and caps out-of-pocket costs for Medicare beneficiaries.

The new code, effective Oct. 1, 2022, allows APDS to be recognized as an distinct immunological disease.

Investigators found that socioeconomic and financial barriers can affect patients’ access to oral cancer medications. They suggest that addressing these barriers could improve adherence.

Prime has removed six drugs from its formularies because generics are now available. One has been removed because it has been discontinued.

Optum has teamed up with Sanofi to provide savings cards for six insulins through the Optum Store.

The prescription drug launches include a therapy to treat adults with multiple myeloma and a treatment for overactive bladder. Dr. Reddy’s has also acquired several therapies from Eton Pharmaceuticals, including hypotension treatments.